Why the study?
What is the best treatment for venous thromboembolism in cancer patients?
What is the best treatment for venous thromboembolism in cancer patients?
This review discusses the efficacy and limitations of various anticoagulants for treating venous thromboembolism in cancer patients, highlighting the issue of poor adherence to published guidelines.
Answers are grounded in this paper and cite their sources.
Anticoagulant options for cancer VTE retain key limitations; leaves open optimal selection and strategies to boost guideline adherence.
The relationship between venous thromboembolism and cancer has been known for many years, and there is solid scientific evidence addressing the adequate treatment of this condition in oncology patients. However, established prescribing habits, individual patient challenges, and uncertainty concerning treatment justifies poor adherence to published guidelines. This paper reviews venous thromboembolism treatment while focusing on vitamin K antagonists, low-molecular-weight heparins, and novel oral anticoagulants, namely in terms of their efficacy and limitations.
No takes yet. Share an insight, caveat, or question.
Miguel Barbosa (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: